Incyte Share Price Today
(NASDAQ: INCY)

Name: Incyte Share Price Today (NASDAQ: INCY) - Incyte Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Incyte share price is $74.16 & ₹6,425.22 as on 1 Feb 2025, 2.30 'hrs' IST

$74.16

▲

0.39

(0.53%)

Market is closed - opens 8 PM, 03 Feb 2025

View live Incyte share price in Dollar and Rupees. Guide to invest in Incyte stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Incyte, along with analyst recommendations, forecasts, and comprehensive financials.

Incyte share price movements

Today's Low: $73.60
Today's High: $75.14
$74.16
0.76%
Downside
Day's Volatility :2.05%
Upside
1.31%
52 Weeks Low: $50.35
52 Weeks High: $83.95
$74.16
32.11%
Downside
52 Weeks Volatility :40.02%
Upside
11.66%

Incyte (INCY) Returns

Period	Incyte Corporation	Sector (Health Care)	Index (Russel 2000)
3 Months	-2.1%	-0.6%	0.0%
6 Months	19.61%	-2.8%	0.0%
1 Year	27.1%	3.3%	0.0%
3 Years	-0.31%	11.6%	-13.7%

Incyte (INCY) Key Statistics

in dollars & INR

Previous Close	$73.77
Open	$73.76
Today's High	$75.1413
Today's Low	$73.6
Market Capitalization	$14.2B
Today's Volume	$1.3M
52 Week High	$83.95
52 Week Low	$50.3498
Revenue TTM	$4.1B
EBITDA	$80.5M
Earnings Per Share (EPS)	$0.09
PE Ratio	819.67
Profit Margin	0.8%
Quarterly Earnings Growth YOY	-0.29%
Return On Equity TTM	0.8%

How to invest in Incyte Stock (INCY) from India?

It is very easy for Indian residents to invest directly in Incyte from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Incyte stock in both Indian Rupees (INR) and US Dollars (USD). Search for Incyte or INCY on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Incyte or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Incyte shares which would translate to 0.012 fractional shares of Incyte as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Incyte, in just a few clicks!

Returns in Incyte (INCY) for Indian investors in Rupees

The Incyte stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Incyte investment value today

Current value as on today

₹1,31,655

Returns

₹31,655

(+31.65%)

Returns from Incyte Stock

₹27,095 (+27.1%)

Dollar Returns

₹4,559 (+4.56%)

Indian investors sentiment towards Incyte (INCY)

-57%

Period: Jan 1, 2025 to Jan 31, 2025. Change in 30 Days versus previous period

Search interest for Incyte Stock from India on INDmoney has decreased by -57% in the last 30 days, reflecting a downward trend in search activity.

Indian Mutual Funds that invest in Incyte Stock (INCY Ticker)

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	1379	-1.83	0.02%

Global Institutional Holdings in Incyte

Baker Bros Advisors LP
15.96%
Vanguard Group Inc
10.58%
BlackRock Inc
8.86%
Dodge & Cox
7.93%
State Street Corp
5.48%
Renaissance Technologies Corp
2.34%

Analyst Recommendation on Incyte

Buy

55%Buy

44%Hold

0%Sell

Based on 29 Wall street analysts offering stock ratings for Incyte(by analysts ranked 0 to 5 stars)

Based on 29 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Incyte Stock (INCY)

What analysts predicted

Upside of 7.54%

Target:

$79.76

Current:

$74.16

Insights on Incyte Stock (Ticker Symbol: INCY)

Price Movement
In the last 7 days, INCY stock has moved up by 2.2%
Increasing Revenue
Revenue is up for the last 3 quarters, 880.88M → 1.13B (in $), with an average increase of 11.9% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -444.60M → 106.45M (in $), with an average increase of 517.6% per quarter
INCY vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 55.1% return, outperforming this stock by 29.7%
INCY vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 87.2% return, outperforming this stock by 88.6%
Price to Sales
ForINCY every $1 of sales, investors are willing to pay $3.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.4 for every $1 of sales.

INCY Incyte Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$1.9B	↑ 22.5%
Net Income	$109.5M	↓ 134.97%
Net Profit Margin	5.82%	↑ 26.2%

	FY19	Y/Y Change
Revenue	$2.2B	↑ 14.71%
Net Income	$446.9M	↑ 308.16%
Net Profit Margin	20.7%	↑ 14.88%

	FY20	Y/Y Change
Revenue	$2.7B	↑ 23.53%
Net Income	$-295.7M	↓ 166.17%
Net Profit Margin	-11.09%	↓ 31.79%

	FY21	Y/Y Change
Revenue	$3.0B	↑ 11.98%
Net Income	$948.6M	↓ 420.79%
Net Profit Margin	31.76%	↑ 42.85%

	FY22	Y/Y Change
Revenue	$3.4B	↑ 13.67%
Net Income	$340.7M	↓ 64.09%
Net Profit Margin	10.04%	↓ 21.72%

	FY23	Y/Y Change
Revenue	$3.7B	↑ 8.87%
Net Income	$597.6M	↑ 75.42%
Net Profit Margin	16.17%	↑ 6.13%

	Q2 FY23	Q/Q Change
Revenue	$954.6M	↑ 18.05%
Net Income	$203.5M	↑ 837.88%
Net Profit Margin	21.32%	↑ 18.64%

	Q3 FY23	Q/Q Change
Revenue	$919.0M	↓ 3.73%
Net Income	$171.3M	↓ 15.86%
Net Profit Margin	18.64%	↓ 2.68%

	Q4 FY23	Q/Q Change
Revenue	$1.0B	↑ 10.26%
Net Income	$201.1M	↑ 17.41%
Net Profit Margin	19.84%	↑ 1.2%

	Q1 FY24	Q/Q Change
Revenue	$880.9M	↓ 13.07%
Net Income	$169.5M	↓ 15.68%
Net Profit Margin	19.25%	↓ 0.59%

	Q2 FY24	Q/Q Change
Revenue	$1.0B	↑ 18.49%
Net Income	$-444.6M	↓ 362.23%
Net Profit Margin	-42.6%	↓ 61.85%

	Q3 FY24	Q/Q Change
Revenue	$1.1B	↑ 9.02%
Net Income	$106.5M	↓ 123.94%
Net Profit Margin	9.36%	↑ 51.96%

	FY18	Y/Y Change
Profit	$1.8B	↑ 22.72%

	FY19	Y/Y Change
Profit	$2.0B	↑ 14.36%

	FY20	Y/Y Change
Profit	$2.5B	↑ 24.01%

	FY21	Y/Y Change
Profit	$2.8B	↑ 11.83%

	FY22	Y/Y Change
Profit	$3.2B	↑ 12.43%

	FY23	Y/Y Change
Profit	$3.4B	↑ 7.94%

	Q2 FY23	Q/Q Change
Profit	$886.3M	↑ 17.88%

	Q3 FY23	Q/Q Change
Profit	$858.9M	↓ 3.09%

	Q4 FY23	Q/Q Change
Profit	$943.5M	↑ 9.85%

	Q1 FY24	Q/Q Change
Profit	$819.9M	↓ 13.11%

	Q2 FY24	Q/Q Change
Profit	$950.8M	↑ 15.96%

	Q3 FY24	Q/Q Change
Profit	$1.1B	↑ 10.63%

	FY18	Y/Y Change
Operating Cash Flow	$336.2M	↓ 461.58%
Investing Cash Flow	$-86.4M	↓ 75.31%
Financing Cash Flow	$14.7M	↓ 97.88%

	FY19	Y/Y Change
Operating Cash Flow	$710.7M	↑ 111.36%
Investing Cash Flow	$-87.5M	↑ 1.19%
Financing Cash Flow	$45.7M	↑ 211.87%

	FY20	Y/Y Change
Operating Cash Flow	$-124.6M	↓ 117.53%
Investing Cash Flow	$-269.0M	↑ 207.59%
Financing Cash Flow	$71.7M	↑ 56.87%

	FY21	Y/Y Change
Operating Cash Flow	$749.5M	↓ 701.52%
Investing Cash Flow	$-207.7M	↓ 22.79%
Financing Cash Flow	$6.2M	↓ 91.39%

	FY22	Y/Y Change
Operating Cash Flow	$969.9M	↑ 29.41%
Investing Cash Flow	$-78.5M	↓ 62.18%
Financing Cash Flow	$-794.0K	↓ 112.86%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$306.5M	↓ 390.26%
Investing Cash Flow	$-7.4M	↓ 73.99%
Financing Cash Flow	$12.9M	↑ 220.98%

Incyte Technicals Summary

Sell

Neutral

Buy

Incyte is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Incyte (INCY) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Incyte Corporation	6.66%	19.61%	27.1%	-0.31%	1.67%
Biontech Se	7.35%	57.95%	33.59%	-31.3%	308.89%
Regeneron Pharmaceuticals, Inc.	-5.9%	-37.18%	-28.8%	8.05%	97.29%
Vertex Pharmaceuticals Incorporated	13.78%	-3.19%	8.71%	82.07%	100.29%
Alnylam Pharmaceuticals, Inc.	16.13%	2.38%	56.77%	86.78%	136.62%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Incyte Corporation	819.67	819.67	0.65	1.31	0.01	0.0	NA	16.45
Biontech Se	160.8	NA	0.04	-3.32	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	16.89	16.89	1.06	44.96	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.15	0.49	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Incyte Corporation	Buy	$14.2B	1.67%	819.67	0.8%
Biontech Se	Buy	$29.0B	308.89%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.1B	97.29%	16.89	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$112.9B	100.29%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$35.7B	136.62%	NA	-15.86%

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation

Organization	Incyte
Employees	2524
CEO	Mr. Herve Hoppenot
Industry	Health Technology

Management People of Incyte

Name	Title
Mr. Herve Hoppenot	CEO & Chairman
Dr. Pablo J. Cagnoni M.D., Ph.D.	President and Head of Research & Development
Ms. Christiana Stamoulis M.B.A.	Executive VP & CFO
Dr. Patrick Mayes Ph.D.	Vice President of Biotherapeutic Research

Important FAQs about investing in INCY Stock from India :

What is Incyte share price today?

Incyte share price today stands at $74.16, Open: $73.76 ; Previous Close: $73.77 ; High: $75.14 ; Low: $73.60 ; 52 Week High: $83.95 ; 52 Week Low: $50.35.

The stock opens at $73.76, after a previous close of $73.77. The stock reached a daily high of $75.14 and a low of $73.60, with a 52-week high of $83.95 and a 52-week low of $50.35.

Can Indians buy Incyte shares?

Yes, Indians can invest in the Incyte (INCY) from India.

With INDmoney, you can buy Incyte at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Incyte at zero transaction cost.

How can I buy Incyte shares from India?

It is very easy to buy Incyte from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Incyte (INCY) be purchased?

Yes, you can buy fractional shares of Incyte with INDmoney app.

What are the documents required to start investing in Incyte stocks?

To start investing in Incyte, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.